NEW YORK (TheStreet) -- CHANGE IN RATINGS
downgraded at Oppenheimer from Outperform to Perform. Valuation call, after the company reported disappointing earnings.
numbers reduced at Goldman. Shares of BAX now seen reaching $56. Estimates also lowered, because of healthcare reform and slower plasma growth. Neutral rating.
downgraded at William Blair from Outperform to Market Perform. Company lowered its forward earnings guidance.
( CBE) upgraded at Longbow from Neutral to Buy. $60 price target. Company is realizing higher margins and has a strong balance sheet.
upgraded at Citi to Hold from Sell on better visibility on revenue trends. Price target surged to $62 from $36. 2010 and 2011 EPS estimates boosted to $2.20 and $3.10, respectively.
numbers upped at Goldman through 2012. Company is cutting costs and looking at double-digit sales growth. Neutral rating and new $48 price target.
upgraded at Baird from Neutral to Outperform. $24 price target. Company is seeing strong sales, especially in the clinical area.
downgraded at Oppenheimer from Outperform to Perform. Shares should be range-bound as the company closes on the Q purchase.
upgraded at Wells from Market Perform to Outperform. Medicaid should help drive higher earnings in 2010.
downgraded at Goldman from Buy to Neutral. $15 price target. Estimates also cut, because of weaker near-term asset flows.
upgraded at Wells from Underperform to Market Perform. Estimates also boosted, following recent channel checks.
downgraded at Jefferies. NOK was downgraded from Hold to Underperform. Company posted poor earnings and has limited sales visibility.
Sirona Dental Systems
upgraded at Barclays to Overweight from Equal Weight on good top line visibility and some sense of additional EBITDA upside. Price target lifted to $48 from $41. 2010 and 2011 EPS estimates held at $2.48 and $2.72, respectively.
downgraded at Goldman to Neutral. $32 price target. Estimates also lowered, given wireline margin pressures.
upgraded at Baird to Outperform from Neutral. $50 price target. Company reported a strong quarter, and guidance should prove to be conservative.
STOCK COMMENTS / EPS CHANGES
cut from Conviction Buy list at Goldman. Stock is up 59% over the past year and lacks near-term catalysts. $62 price target.
estimates tweaked at Citi. AMZN 2010 EPS estimate lowered to $2.89, 2011 raised by a penny to $4.07. Solid Q1 beat with typical conservative guidance. Maintain Buy rating and $180 price target.
estimates, target increased at Goldman. AMZN estimates were raised through 2012. Company is seeing accelerating sales growth. Buy rating and new $180 price target.
estimates, target raised at Goldman. Shares of AN now seen reaching $19. Estimates also increased, given cost cuts and share buybacks. Sell rating.
target, estimates increased at Citi. AXP price target lifted to $55 from $51 on strong 1Q10 numbers. Spending accelerates into March and April. 2010 and 2011 EPS estimates improved to $2.95 and $3.25, respectively. Buy rating.
numbers boosted at FBR. Shares of AXP now seen reaching $48. Estimates also upped, because of improving credit quality. Market Perform rating.
estimates, target raised at Goldman. Shares of AZO now seen reaching $185. Estimates also increased, following channel checks. Neutral rating.
estimates, target raised at FBR. Shares of BBT now seen reaching $30. Estimates also increased, given a wider net interest margin and lower provision expenses. Market Perform rating.
numbers boosted at Goldman. Shares of CAKE now seen reaching $32. Estimates also upped, given better sales and margins. Buy rating.
Capital One Financial
target, estimate boosted at Citi. COF price target raised to $56 from $49 after positive 1Q10 results. Turing the corner on credit. 2010 EPS estimate jumped to $2.90, 2011 held at $3.75. Buy rating.
estimates, target raised at Goldman. Shares of DHR now seen reaching $100. Company is seeing accelerating organic growth. Buy rating.
Dick's Sporting Goods
numbers boosted at Goldman. Shares of DKS now seen reaching $31. Estimates also upped, given better sales expectations. Buy rating.
estimates, target boosted at Goldman. Shares of GGG now seen reaching $35. Estimates also upped, given stronger international sales. Sell rating.
estimates, target raised at Goldman. Shares of HD now seen reaching $38. Estimates also increased, because of better home sales and positive lumber pricing. Buy rating.
estimates, target boosted at Goldman. HSY estimates were upped through 2012. Company is seeing higher sales and margins. Sell rating and new $45 price target.
( KG) numbers cut at Goldman through 2013. Partner pain drug was rejected by an FDA advisory panel. Sell rating and new $10.50 price target.
target lower, estimates mixed at Barclays. KMB price target sunk to $60 from $65 on valuation. A whole bunch of ifs, Barclays said. 2010 EPS estimate lowered to $4.81, 2011 raised to $5.30. Underweight rating.
target, estimates boosted at Barclays. LLL price target increased to $114 from $97 after 1Q10 beat expectations. 2010 and 2011 EPs estimates raised to $8.20 and $9.15, respectively. Maintain Overweight rating.
estimates, target increased at Goldman. LOW estimates were raised through 2012. Company is seeing higher lumber prices and favorable weather trends. Neutral rating and new $29 price target.
estimates, target increased at FBR. MAR estimates were raised through 2011. Company posted a strong quarter and is seeing better demand trends. Market Perform rating and new $38 price target.
target, estimates raised at Citi. MSFT price target lifted to $37 from $32 after inline 3Q10 results. Leading enterprise indicators improve. 2010 and 2011 EPS estimates increased to $2.07 and $2.34, respectively. Reiterate Buy rating.
estimates, target upped at FBR Capital Markets. MSFT estimates were boosted through 2011. Company continues to benefit from the new PC upgrade cycle. Market Perform rating and new $31 price target.
added to Top Picks list at FBR. $80 price target. Company posted the cleanest quarter amongst its peers.
estimates increased at Goldman through 2012. Company is seeing higher sales across the board. Sell rating and new $54 price target.
added to Top Picks list at FBR Capital Markets. $36 price target. Estimates also boosted, given the company's potential operating leverage. Outperform rating.
target, estimates higher at Barclays. RTN price target jumped to $69 from $61 on strong 1Q10 results. 2010 and 2011 EPS estimates set at $5.00 and $5.50, respectively. Reiterate Overweigh rating.
numbers boosted at FBR. Shares of RVBD now seen reaching $29. Estimates also upped, as the company is seeing better deal flow. Market Perform rating.
numbers upped at FBR through 2011. Credit environment is stabilizing. Underperform rating and new $16 price target.
( TLCR) numbers lowered at Goldman through 2014. Company will be hurt by healthcare reform and slower growth in the plasma market. Neutral rating and new $22 price target.
estimates, target increased at Goldman through 2012. Company is seeing better industrial margins. Buy rating and new $30 price target.
numbers raised at FBR. Shares of UNP now seen reaching $88. Estimates also increased, given higher volumes and cost controls. Outperform rating.
estimates, target increased at FBR. WCC estimates were raised through 2011. Pricing is helping to drive organic growth. Outperform rating and new $47 price target.
This article was written by a staff member of TheStreet.com.